dc.contributor.author | Fazekas, Barbara | |
dc.contributor.author | Griffin, Matthew D. | |
dc.date.accessioned | 2021-01-04T14:51:24Z | |
dc.date.issued | 2020-01-28 | |
dc.identifier.citation | Fazekas, Barbara, & Griffin, Matthew D. (2020). Mesenchymal stromal cell–based therapies for acute kidney injury: progress in the last decade. Kidney International, 97(6), 1130-1140. doi:https://doi.org/10.1016/j.kint.2019.12.019 | en_IE |
dc.identifier.issn | 0085-2538 | |
dc.identifier.uri | http://hdl.handle.net/10379/16399 | |
dc.description.abstract | A little over 10 years ago, the therapeutic potential of mesenchymal stromal cells (MSCs) for the treatment of acute kidney injury (AKI) was becoming widely recognized. Since then, there has been further intensive study of this topic with a clear translational intent. Over the past decade, many more animal model studies have strengthened the evidence that systemically or locally delivered MSCs ameliorate renal injury in sterile and sepsis-associated AKI. Some of these preclinical studies have also provided a range of compelling new insights into the in vivo fate and mechanisms of action of MSCs in the setting of AKI and other inflammatory conditions. Coupled with increased knowledge of the functional roles of resident and infiltrating immune cell mediators in determining the severity and outcome of AKI, the progress made in the past decade would appear to have significantly strengthened the translational pathway for MSC-based therapies. In contrast, however, the extent of the clinical experience with MSC administration in human subjects with AKI or sepsis-associated AKI has been limited to a small number of early-phase clinical trials, which appear to demonstrate safety but have not thus far delivered a strong signal of efficacy. In this review, we summarize the most significant new developments in the field of MSC-based therapies as they relate to AKI and reflect on the key gaps in knowledge and technology that remain to be addressed for the true clinical potential of MSCs and, perhaps, other emerging cellular therapies to be realized. | en_IE |
dc.description.sponsorship | BF was supported by an Irish Research Council Enterprise Partnership Postdoctoral Fellowship (grant number EPSPD/2017/106). MDG is supported by grants from the European Commission [Horizon 2020 Collaborative Health Project NEPHSTROM (grant number 634086) and FP7 Collaborative Health Project VISICORT (grant number 602470)], from Science Foundation Ireland [REMEDI Strategic Research Cluster (grant number 09/SRC-B1794; MDG) and CÚRAM Research Centre (grant number 13/RC/2073; MDG)] and the European Regional Development Fund. | |
dc.format | application/pdf | en_IE |
dc.language.iso | en | en_IE |
dc.publisher | Elsevier | en_IE |
dc.relation.ispartof | Kidney International | en |
dc.rights | Attribution-NonCommercial-NoDerivs 3.0 Ireland | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/3.0/ie/ | |
dc.subject | CISPLATIN-INDUCED NEPHROTOXICITY | en_IE |
dc.subject | INDUCED RENAL INJURY | en_IE |
dc.subject | REGULATORY T-CELLS | en_IE |
dc.subject | STEM-CELLS | en_IE |
dc.subject | SEPTIC SHOCK | en_IE |
dc.subject | TUBULOINTERSTITIAL FIBROSIS | en_IE |
dc.subject | HEME OXYGENASE-1 | en_IE |
dc.subject | PROGENITOR CELLS | en_IE |
dc.subject | SEPSIS | en_IE |
dc.subject | PROTECT | en_IE |
dc.title | Mesenchymal stromal cell–based therapies for acute kidney injury: progress in the last decade | en_IE |
dc.type | Article | en_IE |
dc.date.updated | 2020-12-19T17:33:38Z | |
dc.identifier.doi | 10.1016/j.kint.2019.12.019 | |
dc.local.publishedsource | https://doi.org/10.1016/j.kint.2019.12.019 | en_IE |
dc.description.peer-reviewed | peer-reviewed | |
dc.contributor.funder | Irish Research Council | |
dc.contributor.funder | Horizon 2020 | |
dc.contributor.funder | European Regional Development Fund | |
dc.contributor.funder | Science Foundation Ireland | |
dc.description.embargo | 2021-01-28 | |
dc.internal.rssid | 21697342 | |
dc.local.contact | Matthew Dallas Griffin, Remedi, Biomedical Sciences Buil, Corrib Village, Dangan, Nui Galway. 5436 Email: matthew.griffin@nuigalway.ie | |
dc.local.copyrightchecked | Yes | |
dc.local.version | ACCEPTED | |
dcterms.project | info:eu-repo/grantAgreement/EC/H2020::RIA/634086/EU/Novel Stromal Cell Therapy for Diabetic Kidney Disease/NEPHSTROM | |
dcterms.project | info:eu-repo/grantAgreement/EC/FP7::SP1::HEALTH/602470/EU/Adverse Immune Signatures and their Prevention in Corneal Transplantation/VISICORT | |
dcterms.project | info:eu-repo/grantAgreement/SFI/SFI Strategic Research Cluster/09/SRC/B1794/IE/SRC REMEDI: REMEDI-2: From Research to Human Therapy/ | |
dcterms.project | info:eu-repo/grantAgreement/SFI/SFI Research Centres/13/RC/2073/IE/C�RAM - Centre for Research in Medical Devices/ | |
nui.item.downloads | 375 | |